skip to Main Content

New drug combination targets aggressive blood cancer

Safety and efficacy of combining talazoparib with decitabine to treat acute myeloid leukemia (AML) are subject of multi-site clinical trial GRAND RAPIDS, Mich. (March 7, 2017)—A pair of drugs that may be a one-two punch needed to help combat acute…Read More

Van Andel Institute–SU2C
Cancer Epigenetics Dream Team:
The Epigenetics Dream Team II

Epigenetic therapy is an approach to cancer treatment that involves switching key genes on or off to help destroy cancer cells. The Van Andel Institute (VAI)–SU2C Cancer Epigenetics Dream Team II, funded by the Van Andel Institute, continues the original…Read More

TARGETing pediatric blood cancer: Changing treatment for kids

A new molecular map of pediatric acute myeloid leukemia (AML) illuminates previously unknown causes of the disease and may lead to more effective treatment strategies developed specifically for children. Conducted by an international team of scientists and pediatric oncologists, the…Read More

Back To Top